Thursday, December 13, 2018

Versant Backed Akero Therapeutics Gets $70M More

Akero Therapeutics, a biotechnology startup backed by San Diego's Versant Ventures, which developing treatments for non-alcohol steatohepatitis (NASH) and other serious metabolic diseases, has raised $70M in a Series B funding round. According to Akero Therapeutics, the funding was led by Janus Henderson Investors, and also included Redmile Group, Boxer

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.